other material
confidence high
sentiment negative
materiality 0.40
Iovance files audited financials for Proleukin acquisition; FY2022 revenue $21.6M, net loss $10.2M
IOVANCE BIOTHERAPEUTICS, INC.
- Proleukin revenue fell to $21.6M in FY2022 from $40.1M in FY2021; net loss of $10.2M vs profit $7.4M.
- Impairment of intangible assets of $2.7M recorded in FY2022.
- Auditors include going concern material uncertainty due to disposal to Iovance.
- Unaudited pro forma financials for Q1 2023 and FY2022 filed as Exhibit 99.3.